Wanbury Expands Global API Presence with Key Filings and Regulatory Approvals
Wanbury Ltd 路 Press Release 路 08 Oct 2026, 6:34 pm
Wanbury Expands Global API Presence with Key Filings and Regulatory Approvals Wanbury Limited filed a new Drug Master File (DMF) in South Africa for Tramadol HCl API, alongside Metformin HCl API DMF filings in the Philippines and Singapore. The company received EDQM approval after adding Key Starting Materials vendors to secure supply chain continuity for its CEP-filed Paroxetine HCl API. Additionally, Australia鈥檚 TGA accepted Wanbury鈥檚 compliance report for inspectional observations, ensuring uninterrupted API supplies to the Australian market.
Original exchange filing (PDF)
More announcements from Wanbury Ltd
- Disclosure under Regulation 30 of the SEBI LODR, 2015 - Investors Presentation on Q2 and Half Year ended 30.09.2026. 路 18 Nov 2026
- Clarifications on investor queries regarding recent announcement 路 16 Nov 2026
- Wanbury Limited''s Tanuku Plant - US FDA Inspection - Updates 路 16 Nov 2026
- Wanbury Limited received regulatory approval (CADIFA: Letter of suitability for API) from ANVISA (Brazil FDA) for its flagship product Metformin HC1 EP grade. 路 12 Nov 2026
- Press Release on Standalone and Consolidated Un-audited Financial Results for the second quarter & half year ended 30th September, 2026. 路 06 Nov 2026
- Financial Results as on 30th September, 2026 路 05 Nov 2026
- Outcome of the Board Meeting held on November 04, 2026 路 05 Nov 2026
- Wanbury Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 05 Nov 2026
